

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) - Drugs In Development, 2021

<https://marketpublishers.com/r/CF8367E2481FEN.html>

Date: June 2021

Pages: 96

Price: US\$ 2,000.00 (Single User License)

ID: CF8367E2481FEN

Abstracts

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Drugs In Development, 2021, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape.

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive

pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 2, 3 and 2 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in
Therapeutics Development

Argenx SE

Cellenkos Inc

GeNeuro SA

Immupharma Plc

Johnson & Johnson

Octapharma AG

Pfizer Inc

Sanofi

Takeda Pharmaceutical Co Ltd

UCB SA

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drug Profiles

CK-0803 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

forigerimod acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06755347 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-445088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temelimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development

Milestones

Featured News & Press Releases

Feb 12, 2021: U.S. FDA approves PANZYGA for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Feb 02, 2021: argenx issues statement concerning Efgartigimod

Feb 01, 2021: Argenx announces “GO” decision in adhere trial of Efgartigimod in chronic inflammatory demyelinating polyneuropathy following interim analysis

May 18, 2020: Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga (NewGam) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) presented at AAN 2020

Feb 19, 2019: Gliknik to receive \$15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045

Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data

Feb 22, 2018: GeNeuro receives Orphan Drug Designation from the US FDA for GNbAC1 in chronic inflammatory demyelinating polyneuropathy (CIDP)

Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Argenx SE, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Cellenkos Inc, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Immupharma Plc, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Johnson & Johnson, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Sanofi, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by UCB SA, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/CF8367E2481FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF8367E2481FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

